![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DAINIPPON SUMITOMO PHARMA ENTERS INTO PARTNERSHIP AGREEMENT ON ANTI-HYPERTENSION AND HEPATOCELLULAR CANCER DRUGS
DAINIPPON SUMITOMO PHARMA ENTERS INTO PARTNERSHIP AGREEMENT ON ANTI-HYPERTENSION AND HEPATOCELLULAR CANCER DRUGS
Dainippon Sumitomo Pharma (DSP) and Bristol-Myers K.K. (BMKK) have concluded
an agreement on the marketing rights of anti-hypertension and hepatocellular
cancer drug. Under the agreement terms, BMKK will sublicense to DSP the development,
manufacturing/marketing and marketing rights of irbesartan, an anti-hypertension
drug.
JCN
Network
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct